Polycystic Ovarian Syndrome Treatment Market Report 2026

The polycystic ovarian syndrome treatment market size has grown strongly in recent years. It will grow from $5.01 billion in 2025 to $5.4 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increasing prevalence of hormonal disorders among women, improved diagnostic awareness of PCOS, availability of oral contraceptive therapies, expansion of gynecology care services, rising focus on fertility treatments.

The polycystic ovarian syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $7.28 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing demand for personalized pcos treatment plans, growing adoption of insulin-sensitizing agents, expansion of minimally invasive surgical interventions, rising focus on long-term metabolic health management, increased research into novel hormonal therapies. Major trends in the forecast period include growing use of combination drug therapies, rising adoption of lifestyle-integrated treatment approaches, increased focus on early diagnosis and screening, expanding use of hormonal regulation therapies, improved patient awareness and treatment adherence.

The global increase in genetic and hormonal disorders is a major factor contributing to the growth of the polycystic ovarian syndrome (PCOS) treatment market. PCOS is a common hormonal condition affecting premenopausal women worldwide and is associated with reproductive, endocrine, and metabolic irregularities. For instance, in November 2024, according to Public Health Wales, a UK-based national public health agency, the proportion of congenital anomalies among babies born in Wales remained steady at 4.8% of all births in 2023. Additionally, more than 380 rare childhood diseases are classified based on their causes, with cystic fibrosis being the most frequently reported genetic condition, accounting for 330 cases and a prevalence of 3.93 per 10,000 live births. Therefore, the rising incidence of genetic and hormonal disorders globally is expected to support the growth of the polycystic ovarian syndrome treatment market.

The growing impact of lifestyle and dietary changes is expected to further drive the expansion of the polycystic ovarian syndrome treatment market going forward. Lifestyle and dietary changes refer to alterations in daily habits and nutritional intake. Such changes play an important role in the management and treatment of PCOS and are often adopted as a primary or supportive approach to alleviate symptoms and improve overall health outcomes for affected individuals. For instance, in 2024, according to Synadiet, a France-based professional association representing dietary supplement manufacturers and distributors, 61% of French adults reported consuming a dietary supplement within the previous 24 months as of early 2024, an increase from 59% in both 2023 and 2022. Therefore, the rise in lifestyle and dietary changes is contributing to the growth of the polycystic ovarian syndrome treatment market.

Major companies operating in the polycystic ovarian syndrome treatment market are introducing new initiatives, such as dedicated PCOS drug programs, to strengthen their market presence and improve profitability. A PCOS drug program typically combines lifestyle interventions with pharmaceutical treatments to manage PCOS symptoms more effectively. For instance, in April 2023, Celmatix Inc., a US-based biotechnology company, launched its PCOS Drug Program. The primary objective of this program is to enhance ovarian function by targeting the root causes underlying PCOS symptoms. As part of its recent research efforts, Celmatix has identified promising early-stage drug candidates aimed at developing the first oral follicle-stimulating hormone (FSH) receptor therapy.

Major companies operating in the polycystic ovarian syndrome treatment market are Bristol-Myer Squibb Co, Bayer AG, Pfizer Inc., Merck KGaA, Sanofi SA, AstraZeneca PLC, Novartis AG, Teva Pharmaceutical Industries Limited, Abbott Laboratories, Allergan plc, Johnson and Johnson, Ferring Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Organon & Co, Forendo Pharma Ltd., GlaxoSmithKline plc, AbbVie Inc., Eli Lilly and Company, Mylan NV, Lupin Pharmaceuticals Inc., HRA Pharma SAS, CooperSurgical Inc., TherapeuticsMD Inc., Agile Therapeutics Inc., Aurobindo Pharma Limited, Sun Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited, Glenmark Pharmaceuticals Limited.

North America was the largest region in the polycystic ovarian syndrome treatment market in 2025. Western Europe was the second largest region in the polycystic ovarian syndrome treatment market. The regions covered in the polycystic ovarian syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the polycystic ovarian syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the polycystic ovarian syndrome treatment market by increasing costs of imported pharmaceutical ingredients, diagnostic reagents, medical devices, and hormonal therapy formulations. Healthcare providers in North America and Europe are most affected due to dependence on imported drugs and diagnostics, while Asia-Pacific faces cost pressures in pharmaceutical manufacturing and distribution. These tariffs may raise treatment costs and impact accessibility for patients. However, they are also encouraging domestic drug production, localized formulation manufacturing, and regional expansion of women’s health pharmaceutical supply chains.

The polycystic ovarian syndrome treatment market research report is one of a series of new reports that provides polycystic ovarian syndrome treatment market statistics, including polycystic ovarian syndrome treatment industry global market size, regional shares, competitors with a polycystic ovarian syndrome treatment market share, detailed polycystic ovarian syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the polycystic ovarian syndrome treatment industry. This polycystic ovarian syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Polycystic ovarian syndrome is a hormonal disorder in females characterized by an imbalance in hormone levels, including higher than normal levels of male hormones. This imbalance can lead to irregular or missed menstrual periods and can make it more difficult to achieve pregnancy.

The main drug types used in the polycystic ovarian syndrome treatment market include oral contraceptives, ornithine decarboxylase inhibitors, insulin sensitizing agents, anti depressants, diuretics, and aromatase inhibitors. Oral contraceptives are hormone based medications taken by mouth to prevent pregnancy by suppressing ovulation and blocking sperm from entering the cervix. Surgical treatment options include ovarian wedge resection and laparoscopic ovarian drilling. These procedures are carried out in hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, and feminist health centers.

The polycystic ovarian syndrome treatment market includes revenue earned by first line drugs for treating hirustism, first line drugs for ovulation, and insulin sensitizing drugs. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.